A ‘designer’ manganese-peptide antioxidant of the world’s toughest bacterium, combined with radiation, have shown to be successful in the development of a vaccine to counter Venezuelan Equine Encephalitis Virus (VEEV), a biothreat agent, and Chikungunya virus, a mosquito-borne illness causing severe outbreaks around the world, according to a study “Deinococcus Mn2+-Peptide Complex: A Novel Approach to Alphavirus Vaccine Development,” published online May 30 in the journal, Vaccine, published by Elsevier, http://www.sciencedirect.com/
Effective vaccines depend upon the human immune system recognizing a biological structure that is similar to that of a disease-causing organism. A manganese-peptide antioxidant complex of Deinococcus, developed by Uniformed Services University of the Health Sciences (USU) pathology professor Dr. Michael J. Daly and his team, has the remarkable property of protecting proteins from ionizing radiation damage but not protecting the genetic material (DNA or RNA) in viruses and bacteria. Using D. radiodurans, listed in the Guinness Book of World Records as “the world’s toughest bacterium” and which can withstand 3,000 times the levels of gamma radiation that human cells can, Daly found that a disease-causing organism (pathogen) can be exposed to gamma radiation in the presence of a Deinococcus Mn complex, and rendered non-replicative (killed) by overwhelming genetic damage, but still maintain the shape of key surface proteins needed to mount a highly protective immune response. This approach was successfully implemented on viruses for the first time by scientists in the USU lab of the late Dr. Radha K. Maheshwari to produce vaccines against VEEV and Chikungunya virus.
This approach offers a simple, rapid, cost effective and potentially universal inactivation strategy that can be applied to any pathogen requiring immediate attention, for example, Ebola and Zika viruses.
“Application of this methodology has the potential to revolutionize all future vaccine development” says Dr. Paridhi Gupta, a scientist in the Maheshwari laboratory, and the study’s co-lead author.
The Latest on: Vaccine development
- Vaccine exemption rates among US kindergartners continue to climb, CDC sayson October 18, 2019 at 10:36 am
dean for the National School of Tropical Medicine at the Baylor College of Medicine in Houston and co-director of the Texas Children's Hospital Center for Vaccine Development, who was not involved in ...
- Combating MERS in camels with a single-dose vaccineon October 18, 2019 at 10:15 am
One approach to tackle MERS is to use vaccines made from unarmed viruses that are efficient in triggering the development of a strong immune response against other dangerous viruses. ‘Viral vector ...
- Data Sheet on Conjugate Vaccine Market 2018-2023|industry Trends, Development, Revenue, Demandon October 18, 2019 at 7:42 am
Oct 18, 2019 (AmericaNewsHour) -- Increased adoption of therapeutic vaccines for cancer, improved patient compliance, a larger product pipeline, and efforts to promote adoption of screening methods ...
- With European backing, the world is on the brink of the first approved Ebola vaccineon October 18, 2019 at 6:09 am
WHO Director-General Tedros Adhanom Ghebreyesus called the EMA news “a triumph for public health,” saying development of this vaccine is the result of an “unprecedented collaboration between scores of ...
- Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Diseaseon October 18, 2019 at 3:47 am
“Our work would not have been possible without the efforts of countless numbers of people, especially those from the World Health Organization and many other government and non-governmental ...
via Google News and Bing News